Further support the development of six preparations against it coronavirus, which are entering a phase of clinical trials, the Ministries of Education and Health announced on Monday Germany.
According to the Minister of Education Anya Karlicek and the Minister of Health Jens Span, these are the plans of the companies AdrenoMed, Apogenix, Αtriva Therapeutics, CORAT Therapeutics, InflaRX and DRK Baden-Würtenberg-Hesse, which will be co – financed by the German government in total 150 million euros, transmitted by ΑΠΕ ΜΠΕ.
“For a few weeks now Delta variant shows us that unfortunately we should take it for granted that they will exist in the future cases coronavirus.
Even if vaccines Covid-19 are widely available, not everyone will be able to get the vaccine.
They are therefore needed more effective drugs for the treatment of patients and due to the different severity of the different stages of the disease, patients need different treatments. “So a wide range of treatments is needed,” Karlicek said, announcing the government’s decision at a joint news conference with Health Minister Jens Spann. of the pandemic “.
“So we are taking care of the development of new drugs, in order to offer treatment to the patients. And we invest in future“because in this way we also strengthen the research and biotechnology sector in Germany”, Mr. Span noted.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
